Can less really be more in melanoma?

Abstract

The incidence of melanoma is increasing worldwide, and the treatment options for patients have been rapidly expanding. However, 5–8% of patients develop metastases between the primary tumor and the draining lymph nodes—known as in-transit metastases, or IT-mets. A long-established protocol for treating patients that develop IT-mets has been refined, but a recent assessment by a team from Rotterdam has indicated that the treatment doses might need to be re-evaluated.